FDA Approval for CINVANTI issued to HERON THERAPS INC
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2026 | Buy → Hold | Needham | |
| 6/9/2025 | $6.00 | Buy | H.C. Wainwright |
| 6/13/2024 | $7.00 | Buy | Rodman & Renshaw |
| 4/23/2024 | $6.00 | Overweight | CapitalOne |
| 3/13/2024 | $4.00 → $5.00 | Buy | Needham |
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling
Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling
Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC ("Azurity"), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable emul
Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigationReaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million Adjusted EBITDA CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates. "Despite typical first-quarter seasonality and unusual weather-related dis
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the
Needham downgraded Heron Therapeutics from Buy to Hold
H.C. Wainwright initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $6.00
Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025. Mr. Cusack has more than 20 years of experience in investment management and corporate finance.
CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera
Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigationReaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million Adjusted EBITDA CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates. "Despite typical first-quarter seasonality and unusual weather-related dis
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the
– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of He
SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)
SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)
SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)